54gene Revenue and Competitors

Location

$44.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • 54gene's estimated annual revenue is currently $39.5M per year.(i)
  • 54gene's estimated revenue per employee is $193,750
  • 54gene's total funding is $44.7M.

Employee Data

  • 54gene has 204 Employees.(i)
  • 54gene grew their employee count by -48% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$15.3M99-49%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.5M29-6%N/AN/A
#10
$9.6M62-7%N/AN/A
Add Company

54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

keywords:N/A

$44.7M

Total Funding

204

Number of Employees

$39.5M

Revenue (est)

-48%

Employee Growth %

N/A

Valuation

N/A

Accelerator

54gene News

2021-09-16 - 54gene Raises $25M in Series B Funding

54gene, a Washington, DC-based health technology company, raised $25M in Series B funding. The round, which brought total funding raised to date to more than $45M since being founded in 2019, was led by Cathay AfricInvest Innovation Fund with participation from Adjuvant Capital, KdT Ventures, P ...

2021-09-16 - 54gene Closes $25M Series B to Advance Global Drug Discovery Capabilities

WASHINGTON, Sept. 16, 2021 /PRNewswire/ -- 54gene, the health technology company advancing African genomics research for improved global health outcomes, has secured $25M in a Series B round, led by Cathay AfricInvest Innovation Fund. The round also included participation from Adjuvant Capital ...

2020-04-14 - 54gene Raises $15M in Series A Funding

54gene, a Nigerian genomics research, services, and development company, closed a Series A round of $15M. The round was led by Adjuvant Capital, a life sciences fund backed by the International Finance Corporation, Novartis, and the Bill & Melinda Gates Foundation, with participation from Raba ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$47.1M204-7%N/A
#2
$50.9M20419%N/A
#3
$22.4M2049%N/A
#4
$15M20411%N/A
#5
$73.6M20413%N/A